Microfluidic device for generation of large, precisely-defined, diverse lipid nanoparticle libraries for screening LNP formulations.
A method to combine two or three monoclonal antibodies (mABs) into one treatment to successfully bind to multiple cancer cell surface epitopes and promote targeted degradation by phagocytosis.
Antigen-specific immunotherapy with engineered cytotoxic T cells targeting misformed proteins to treat neurodegenerative and muscular diseases.
A Switchable Bispecific T-Cell Nanoengager (sBiTNE) to link T cells with cancer cells that can be reversed if off-tumor toxicity is detected.
A method to streamline the process of generating chimeric antigen receptor (CAR) T cells for therapeutic applications.
CAR-T cells are PEGylated to block the interactions with monocytes and macrophages to reduce the side effects of CAR-T cell therapies (cytokine release syndrome and neurotoxicity).
Using mRNA-LNPs to deliver forkhead box protein 3 (Foxp3) to CD4+ T cells to engineer Foxp3-positive T (FP3T) cells with immunosuppressive properties.
Researchers developed an LNP-mRNA-based vaccine that encodes different cytokine mRNAs, as a method to enhance CD8+ T cell responses and memory formation.
Co-expression of modified chimeric antigen receptor (CAR) T cells and cholesterol 25-hydroxylase (CH25H) in a single construct for treatment of solid tumor and hematological cancers.
A platform to isolate and expand CD137-positive (CD137pos) tumor-infiltrating lymphocytes (TILs) to use in adoptive immunotherapy and translational studies.